HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use TOVIAZ safely and effectively. See full prescribing information for TOVIAZ.
TOVIAZ (fesoterodine fumarate) extended-release tablets, for oral use
Initial U.S. Approval: 2008 INDICATIONS AND USAGEToviaz is indicated for the treatment of: - •
- Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. (1.1)
- •
- Neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older and weighing greater than 25 kg. (1.2)
DOSAGE AND ADMINISTRATION- •
- OAB in Adults: The recommended starting dosage is 4 mg orally once daily. Based upon individual response and tolerability, increase to the maximum dosage of 8 mg once daily. (2.1)
- •
- NDO in Pediatric Patients 6 Years and Older:
- •
- Pediatric Patients Weighing Greater than 25 kg and up to 35 kg:
The recommended dosage is 4 mg orally once daily. If needed, dosage may be increased to 8 mg orally once daily. (2.2) - •
- Pediatric Patients Weighing Greater than 35 kg:
The recommended starting dosage is 4 mg orally once daily. After one week, increase to 8 mg orally once daily. (2.2)
- •
- Adult or Pediatric Patients with Renal Impairment: Refer to the full prescribing information for recommended dosage. (2.3, 2.4)
- •
- Dosage Modifications Due to Strong CYP3A4 Inhibitors: Refer to the full prescribing information for recommended dosage. (2.5)
- •
- Administration: Swallow whole with liquid. Do not chew, divide, or crush. Take with or without food. (2.6)
DOSAGE FORMS AND STRENGTHSExtended-release tablets: 4 mg and 8 mg (3) CONTRAINDICATIONS- •
- Known or suspected hypersensitivity to Toviaz or any of its ingredients or to tolterodine tartrate tablets or tolterodine tartrate extended-release capsules. (4)
- •
- Urinary retention (4)
- •
- Gastric retention (4)
- •
- Uncontrolled narrow-angle glaucoma. (4)
WARNINGS AND PRECAUTIONS- •
- Angioedema: Promptly discontinue Toviaz and provide appropriate therapy. (5.1)
- •
- Urinary Retention: Toviaz is not recommended in patients with clinically significant bladder outlet obstruction because of the risk of urinary retention. (5.2)
- •
- Decreased Gastrointestinal Motility: Toviaz is not recommended for use in patients with decreased gastrointestinal motility, such as those with severe constipation. (5.3)
- •
- Worsening of Narrow-Angle Glaucoma: Use Toviaz with caution in patients being treated for narrow-angle glaucoma. (5.4)
- •
- Central Nervous System Effects: Somnolence has been reported with Toviaz. Advise patients not to drive or operate heavy machinery until they know how Toviaz affects them. (5.5)
- •
- Worsening of Myasthenia Gravis Symptoms: Use Toviaz with caution in patients with myasthenia gravis. (5.6)
ADVERSE REACTIONS- •
- Most frequently reported adverse events with Toviaz in adult patients with OAB (≥4%) were: dry mouth (placebo, 7%; Toviaz 4 mg, 19%; Toviaz 8 mg, 35%) and constipation (placebo, 2%; Toviaz 4 mg, 4%; Toviaz 8 mg, 6%). (6.1)
- •
- Most frequently reported adverse reactions with Toviaz in pediatric patients (≥2%) with NDO were: diarrhea, urinary tract infection (UTI), dry mouth, constipation, abdominal pain, nausea, weight increased, and headache. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 2/2024 |